Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Anthera Pharmaceuticals Inc : Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2013 | 02:05pm CEST

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated ("Anthera" or the "Company") (Nasdaq: ANTH) concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for its executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Request more information now by clicking here: www.faruqilaw.com/ANTH

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold ANTH shares and you would like to discuss your legal rights, visit www.faruqilaw.com/ANTH. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(Nasdaq: ANTH)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANTA PHAR
03/20 ANTH The Law Offices of Vincent Wong Reminds Investors of a Class Action Invo..
03/16 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
03/16 ANTHERA PHARMACEUTICALS,INC. (NASDAQ : ANTH) Files An 8-K Entry into a Material ..
03/16 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other ..
03/15 ANTHERA PHARMACEUTICALS : Announces Pricing of $15.0 Million Public Offering of ..
03/14 Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of..
03/14 ANTHERA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock and..
03/13 Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock an..
03/02 ROBBINS ARROYO LLP : Anthera Pharmaceuticals, Inc. ANTH Misled Shareholders Acco..
03/01 Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 Fr..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs